Abstract
A challenge to the prevention of prostate cancer is its fundamental basis; a man who is disease-free must take an agent that might have side-effects to reduce his risk of disease. Although the lifetime risk of prostate cancer in the USA is 18% [3], the converse is that the use of preventive agents in the USA is unnecessary in at least 82% of men. With this in mind, before the PCPT it was not certain whether chemoprevention studies could be completed, given that a healthy, asymptomatic population was required to be enrolled. Other challenges include the need for regular dosing, regular follow-up, and even prostate biopsy in some designs. Despite these challenges, three phase III studies and one relatively large phase IIB study were successfully completed, i.e. the PCPT (finasteride) [4], the REDUCE trial (dutasteride) [5], the SELECT trial (selenium, α -tocopherol) [6] and the GTX-006-211 (toremifene) [7].
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call